Skip to main navigation Skip to search Skip to main content

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B

  • David L. Veenstra
  • , Sean D. Sullivan
  • , Lauren Clarke
  • , Uche H. Iloeje
  • , Eskinder Tafesse
  • , Adrian Di Bisceglie
  • , Kris V. Kowdley
  • , Robert G. Gish

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)963-977
Number of pages15
JournalPharmacoEconomics
Volume25
Issue number11
DOIs
StatePublished - 2007
Externally publishedYes

ASJC Scopus Subject Areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Keywords

  • Adefovir, therapeutic use
  • Cost utility
  • Entecavir, therapeutic use
  • Hepatitis B, treatment
  • Lamivudine, therapeutic use
  • Research and development

Cite this